View allAll Photos Tagged stemcells
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Deanna (my sister) could not resist taking a picture of me with the do-rag given to me by volunteer services.
Phil Holliday, European Advisor, UK Research Office (UKRO)
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Adam Heathfield, Director Science Policy Europe, Pfizer
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
International conference on Cancer Science & Stem Cell Research 2019
Date : 29-30 July, 2019
Venue-Park Plaza Hotel Amsterdam Airport
More info: cancerscience@medicalconferences.nl
+31728080590
more : www.medicalconferences.nl/abstract_submission/Cancer-Scie...
Arnd Hoeveler, Head of Unit, Advanced Therapies and Systems Medicine, DG Research & Innovation, European Commission
Richard L. Hudson, CEO & Editor, Science|Business
Keith Thompson, CEO, Cell Therapy Catapult Centre
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Jonathan Brenton, British Ambassador to Belgium
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Susana Getman, Market Access and Compliance Specialist, US Mission to the EU
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Duane Schulthess, Commercial Director, Science|Business
Ruth McKernan, Chief Scientific Officer, Neusentis, Pfizer
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Chronic back pain stem cell treatment could cut need for opioids: bit.ly/2lbjbdU #TuesdayThoughts #stemcells #science
Arnd Hoeveler, Head of Unit, Advanced Therapies and Systems Medicine, DG Research & Innovation, European Commission
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Image of a stemcell provided by the Virgin Health Bank, currently involved in setting up a cord blood bank in Qatar: www.qatarvisitor.com/index.php?cID=414&pID=1514
Emmanuelle Rial-Sebbag, Permanent Researcher in Biolaw and Bioethics, Inserm
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
An embryonic stem cell cluster (red and blue) being coaxed to differentiate into nerves (green). The nerves grow radially and express the characteristics of nerves that control movement in vertebrates. The red and blue areas are indicative of specific cell proteins that are present only in stem cells. The implication is that researchers have gained significant insight into the chemical and genetic underpinnings of nerve development from naive cell types (stem cells).